Oral Adjuvant Chemotherapy with S-1 or Uracil-tegafur versus Surgery Alone in Patients with Biliary Tract CancerOsamu Itano1*, Naokazu Chiba2, Masatsugu Ishii1, Masahiro Shinoda1, Minoru Kitago1, Yuta Abe1, Taizo Hibi1, Hiroshi Yagi1, Motohide Shimazu3 and Yuko Kitagawa1
- *Corresponding Author:
- Osamu Itano
Department of Surgery, Keio University
School of Medicine, Tokyo, Japan
E-mail: [email protected]
Received date: September 09, 2015 Accepted date: November 28, 2015 Published date: December 06, 2015
Citation: Itano O, Chiba N, Ishii M, Shinoda M, Kitago M et al. (2015) Oral Adjuvant Chemotherapy with S-1 or Uracil-tegafur versus Surgery Alone in Patients with Biliary Tract Cancer. Chemo Open Access 4:174. doi:10.4172/2167-7700.1000174
Copyright: © 2015 Itano O, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract Objective: We compared the influence of postoperative adjuvant chemotherapy with oral anticancer drugs (S-1 or uracil-tegafur [UFT]) and the influence of surgery alone on overall survival (OS) and disease-free survival (DFS) in patients with biliary tract cancer. Methods: This retrospective study included 108 patients with gallbladder cancer (n=22) or bile duct cancer (n=86), who underwent curative resection. The patients were divided into surgery alone (n=58), UFT (n=39; 400 mg/m2/day), and S-1 groups (n=11; 80 mg/m2, days 1–28, twice daily), and outcomes and adverse effects were compared. Results: The 2-year DFS rate was significantly higher in the S-1 group than in the surgery alone group for all patients (72.7% vs. 32.8%, p=0.046). For the patients with gallbladder cancer, the 2-year OS and DFS rates were significantly higher in the UFT group than in the surgery alone group (36.4% vs.0%, p=0.033 and 27.4% vs. 0% p=0.032, respectively; log-rank test). For patients with lymph node metastasis, the 2-year OS and DFS rates were significantly higher in the S-1 group than in the surgery alone group (71.4% vs. 18.2%, p=0.039 and 71.4% vs. 18.2%, p=0.026, respectively) Conclusion: Postoperative adjuvant chemotherapy might improve both the OS and DFS rates, particularly in patients with gallbladder cancer and those with biliary tract cancer and lymph node metastasis.